Liquidia Corporation Common Stock (LQDA)

Price$58.74

Value ScoreF

Growth ScoreA

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)100.67%

Price vs S&P 500 (4W)57.22%

VGM Score66.82

Market Capitalization$5.50B

All Metrics

Book Value / Share (Quarterly)$1.23

P/TBV (Annual)13.48x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)114.96%

Cash Flow / Share (Quarterly)$0.44

Price vs S&P 500 (YTD)68.42%

Gross Margin (TTM)91.82%

Net Profit Margin (TTM)7.74%

EPS (TTM)$0.16

10-Day Avg Trading Volume1.39M

EPS Excl Extra (TTM)$0.16

Revenue Growth (5Y)192.46%

EPS (Annual)$-0.80

ROI (Annual)-66.82%

Gross Margin (Annual)91.64%

Net Profit Margin (5Y Avg)-387.10%

Cash / Share (Quarterly)$2.52

P/E Basic Excl Extra (TTM)246.63x

Revenue Growth QoQ (YoY)4158.49%

ROA (Last FY)-55.78%

Revenue Growth TTM (YoY)1936.66%

EBITD / Share (TTM)$0.51

ROE (5Y Avg)-103.21%

Operating Margin (TTM)15.81%

Cash Flow / Share (Annual)$-1.20

P/B Ratio50.66x

P/B Ratio (Quarterly)30.63x

Net Income / Employee (Annual)$-319,100

EV / Revenue (TTM)18.94x

Net Interest Coverage (TTM)-2.93x

ROA (TTM)7.06%

EV / EBITDA (TTM)117.82x

EPS Incl Extra (Annual)$-0.80

Current Ratio (Annual)4.40x

Quick Ratio (Quarterly)1.98x

3-Month Avg Trading Volume1.54M

52-Week Price Return312.40%

P/E Incl Extra (TTM)246.63x

Revenue / Employee (TTM)$1,333,600

Tangible BV / Share (Quarterly)$1.20

P/S Ratio (Annual)34.75x

Asset Turnover (Annual)0.06x

52-Week High$63.46

Operating Margin (5Y Avg)-368.89%

EPS Excl Extra (Annual)$-0.80

CapEx CAGR (5Y)53.23%

26-Week Price Return116.60%

Quick Ratio (Annual)4.26x

13-Week Price Return100.91%

Total Debt / Equity (Annual)1.49x

Current Ratio (Quarterly)2.22x

Enterprise Value$5.46B

Revenue / Share Growth (5Y)142.81%

Asset Turnover (TTM)0.91x

Book Value / Share Growth (5Y)-6.05%

Revenue / Employee (Annual)$733,000

Pretax Margin (Annual)-43.53%

Cash / Share (Annual)$2.07

3-Month Return Std Dev68.71%

Gross Margin (5Y Avg)78.34%

Net Income / Employee (TTM)$103,300

ROE (Last FY)-166.61%

Net Interest Coverage (Annual)2.36x

EPS Basic Excl Extra (Annual)$-0.80

Receivables Turnover (TTM)7.64x

EV / Free Cash Flow (TTM)139.38x

Total Debt / Equity (Quarterly)1.64x

EPS Incl Extra (TTM)$0.16

Receivables Turnover (Annual)3.86x

ROI (TTM)9.43%

P/S Ratio (TTM)19.10x

Pretax Margin (5Y Avg)-387.10%

Revenue / Share (Annual)$1.84

Tangible BV / Share (Annual)$0.87

Forward P/E14.96x

Price vs S&P 500 (52W)284.19%

P/E Ratio (TTM)246.63x

Year-to-Date Return79.36%

5-Day Price Return1.44%

EPS Normalized (Annual)$-0.80

ROA (5Y Avg)-50.21%

Net Profit Margin (Annual)-43.53%

Month-to-Date Return57.77%

Cash Flow / Share (TTM)$-0.86

EBITD / Share (Annual)$-0.60

Operating Margin (Annual)-32.45%

LT Debt / Equity (Annual)0.92x

P/CF (TTM)114.65x

ROI (5Y Avg)-61.19%

P/E Excl Extra (TTM)246.63x

LT Debt / Equity (Quarterly)1.18x

EPS Basic Excl Extra (TTM)$0.16

P/TBV (Quarterly)31.46x

P/B Ratio (Annual)12.93x

Inventory Turnover (TTM)1.58x

Pretax Margin (TTM)9.10%

Book Value / Share (Annual)$0.91

Price vs S&P 500 (13W)91.16%

Beta0.60x

Revenue / Share (TTM)$2.85

ROE (TTM)46.82%

52-Week Low$11.85

vGradeF

gGradeA

mGradeA

vgmGradeB

Show chart for

Earnings Surprise History

Q1 260.52est. 0.42

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
LQDALiquidia Corporation Common Stock	F	A	A	$58.74
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Liquidia Corp is a biopharmaceutical company focused on pulmonary hypertension and related lung diseases. The company leverages proprietary PRINT technology to engineer uniform drug particles, enabling its lead product YUTREPIA (treprostinil) inhalation powder, while also generating revenue from Treprostinil Injection sales.